Willis Towers Watson faces securities fraud probe after Q1 revenue growth disappoints and shares drop 12%.

Willis Towers Watson reported weaker-than-expected Q1 2026 results, with revenue of $2.41 billion and only 3% organic growth, alongside an 80 basis point decline in operating margin. The company cited geopolitical uncertainty and delayed client projects as reasons for slower growth in its Health, Wealth & Career and Risk & Broking segments. Following this, its stock price fell nearly 12%. Pomerantz LLP has launched an investigation into potential securities fraud or unlawful practices by the company and its officers, signaling possible legal challenges ahead for investors.